August 08, 2018 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Revenues of $1,593,000 USD. Previously, on May 10, 2018, La Jolla Pharmaceutical Co. reported Revenues of $809,000 USD. This represents a change of 96.91% in Revenues.

LJPC / La Jolla Pharmaceutical Co. Revenues
Embed this chart! (it updates automatically)
<a href="https://fintel.io/fg/us/ljpc/Revenues"><img src="https://images.fintel.io/us-ljpc-revenues.png" alt="LJPC / La Jolla Pharmaceutical Co. Revenues"><a>
Period EndPeriodValue
2018-06-30 2018-Q2 1,593,000
2018-03-31 2018-Q1 809,000
2017-09-30 2017-Q3 0
2017-06-30 2017-Q2 0
2017-03-31 2017-Q1 0
2016-12-31 2016-Q4 85,000
2016-09-30 2016-Q3 44,000
2016-06-30 2016-Q2 253,000
2016-03-31 2016-Q1 234,000
2015-12-31 2015-Q4 410,000
2015-09-30 2015-Q3 647,000
2015-06-30 2015-Q2 0
2015-03-31 2015-Q1 0
2014-12-31 2014-Q4 0
2014-09-30 2014-Q3 0
2014-06-30 2014-Q2 0
2014-03-31 2014-Q1 0
AllocatedShareBasedCompensationExpense CostsAndExpenses GeneralAndAdministrativeExpense IncomeTaxExaminationPenaltiesAndInterestExpense IncomeTaxExpenseBenefit IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets LeaseAndRentalExpense OtherNonoperatingIncomeExpense PrepaidExpenseAndOtherAssetsCurrent ResearchAndDevelopmentExpense RevenueFromRelatedParties Revenues WarrantGrantstoThirdPartiesCompensationExpense

Related News Stories

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-16 seekingalpha
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-4)

CUSIP: 503459604